HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

DPP-IV inhibitor may affect spermatogenesis.

Abstract
A 39-year-old physician was diagnosed retrograde ejaculation due to diabetes and treated with amoxapine. This treatment was effective; he could ejaculate. He began receiving DPP-IV inhibitor (Sitagliptin 50 mg, daily), in lieu of insulin injection. Unusual effect on semen quality was occurred following the administration of the drug.
AuthorsHatsuki Hibi, Tadashi Ohori, Yoshiaki Yamada
JournalDiabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 93 Issue 2 Pg. e74-e75 (Aug 2011) ISSN: 1872-8227 [Electronic] Ireland
PMID21636156 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Chemical References
  • Dipeptidyl-Peptidase IV Inhibitors
  • Neurotransmitter Uptake Inhibitors
  • Pyrazines
  • Triazoles
  • Amoxapine
  • Sitagliptin Phosphate
Topics
  • Adult
  • Amoxapine (therapeutic use)
  • Diabetes Mellitus, Type 2 (complications, drug therapy)
  • Dipeptidyl-Peptidase IV Inhibitors (adverse effects, therapeutic use)
  • Ejaculation (drug effects)
  • Humans
  • Male
  • Neurotransmitter Uptake Inhibitors (therapeutic use)
  • Pyrazines (adverse effects, therapeutic use)
  • Semen Analysis
  • Sitagliptin Phosphate
  • Spermatogenesis (drug effects)
  • Triazoles (adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: